Home » AGEB Journal » Issues » Volume 82" » Fasc.1 - Original articles » Article details

Diagnostic hepatitis C testing of people in treatment for substance use disorders in Belgium between 2011 and 2014 : a cross-sectional study

Journal Volume 82 - 2019
Issue Fasc.1 - Original articles
Author(s) L. Van Baelen, J. Antoine, K. De Ridder, G. Muyldermans, L. Gremeaux
Full article
Full Article
VIEW FREE PDF
Department of Public Health and Surveillance, SciensanO. Brussels, Belgium.

Background : Hepatitis C prevalence figures for people who use drugs in Belgium are scarce, and particularly for people who inject drugs. The current study refines the existing HCV estimates by focussing on diagnostic HCV testing practices for this population at risk. Methods : The analysis is the result of a descriptive cross- sectional study, based on data extracted from the linkage between a database of people in treatment for substance use disorders in Belgium and a database of the Belgian health insurance companies. By using national nomenclature codes for HCV tests, the number of people in treatment for substance use disorders who were tested on HCV, were estimated. Results : 18,880 out of 30,905 patients (61.1%) in treatment for substance use disorders between 2011 and 2014 have been screened at least once for HCV between 2008 and 2015. 58.0% of those who had never injected and 59.1% of those with an unknown injecting status were tested for HCV, compared to 86.5% of the patients who had recently injected and 84.5% of those who had ever injected. 36.8% of the people who had recently injected were tested for HCV RNA. Conclusions : This study supports the need of a continued effort of health care providers to identify people infected with HCV. For a population at risk such as people who use drugs, regular screening is needed to reach the goal set by WHO of near viral elimination of HCV by 203O.(Acta gastroenterol. belg., 2019, 82, 35-42).

© Acta Gastro-Enterologica Belgica.
PMID 30888752